Long-term impact of the 70-gene signature on breast cancer outcome.

Several studies have validated the prognostic value of the 70-gene prognosis signature (MammaPrint(R)), but long-term outcome prediction of these patients has not been previously reported. The follow-up of the consecutively treated cohort of 295 patients (<53 years) with invasive breast cancer (T1-2N0-1M0; n = 151 N0, n = 144 N1) diagnosed between 1984 and 1995, in which the 70-gene signature was previously validated, was updated. The median follow-up for this series is now extended to 18.5 years. A significant difference is seen in long-term distant metastasis-free survival (DMFS) for the patients with a low- and a high-risk 70-gene signature (DMFS p < 0.0001), as well as separately for node-negative (DMFS p < 0.0001) and node-positive patients (DMFS p = 0.0004). The 25-year hazard ratios (HRs) for all patients for DMFS and OS were 3.1 (95 % CI 2.02-4.86) and 2.9 (95 % CI 1.90-4.28), respectively. The HRs for DMFS and OS were largest in the first 5 years after diagnosis: 9.6 (95 % CI 4.2-22.1) and 11.3 (95 % CI 3.5-36.4), respectively. The 25-year HRs in the subgroup of node-negative patients for DMFS and OS were 4.57 (95 % CI 2.31-9.04) and 4.73 (95 % CI 2.46-9.07), respectively, and for node-positive patients for DMFS and OS were 2.24 (95 % CI 1.25-4.00) and 1.83 (95 % CI 1.07-3.11), respectively. The 70-gene signature remains prognostic at longer follow-up in patients <53 years of age with stage I and II breast cancer. The 70-gene signature's strongest prognostic power is seen in the first 5 years after diagnosis.

Introduction

Gene-expression signatures, such as the 70-gene signature (MammaPrintR), were developed to assess the risk of distant recurrence in the first 5 years after diagnosis to predict outcome of breast cancer patients [1]. The 70-gene signature was extensively validated in several retrospective studies [2-4]. The test was mainly validated in systemically untreated patients with estrogen-receptor (ER) positive and negative invasive breast cancer, <55 or 60 years, with no axillary nodal involvement. Subsequently, multiple studies validated this signature for additional subgroups such as patients up to 70 years of age, postmenopausal patients, patients with up to three positive lymph nodes and patients with human epidermal growth factor receptor 2 (HER2)-positive disease [5-7]. More recently, the first prospective data on the 70-gene signature were published showing an excellent overall survival for patients with a low risk for recurrence estimation by the 70-gene signature. Even when these low-risk patients did not receive adjuvant chemotherapy, despite ‘high risk’ clinicopathological factors, they had a 5-year distant recurrence-free interval of 100 % [8].

In studies on the prognostic value of the 70-gene signature published so far, the median follow-up was between 5 and 13.6 years. To our knowledge, no data on long-term survival of patients for whom data from a gene signature, such as the 70-gene signature, OncotypeDx recurrence score or PAM50, are available have been published [9, 10]. We therefore set out to update the follow-up of the previously published 70-gene signature consecutive 295 patient cohort, as published by van de Vijver et al. in 2002, to investigate the long-term outcome of breast cancer patients and to evaluate the effect of the 70-gene signature after longer follow-up [4].

Patients and methods

NKI 295

Follow-up was updated until September 2013 for a cohort of 295 consecutive patients diagnosed with primary breast cancer. Study design, patient eligibility and study logistics of the study have been described before [4]. In short, all patients were female, younger than 53 years with histologically proven, operable, invasive breast cancer (T1-2N0-1M0). All were diagnosed at the Netherlands Cancer Institute between 1984 and 1995. 151 of the 295 patients had node-negative disease; 144 patients had node-positive disease. All patients were primarily treated with breast-conserving surgery or mastectomy. Adjuvant treatment consisted of radiotherapy, chemotherapy and/or endocrine therapy as indicated by guidelines used at the time of treatment.

70-gene signature

For all patients included in these analyses, a 70-gene signature result was available. Frozen tumor samples from each patient were processed at the Netherlands Cancer Institute and Rosetta Inpharmatics for RNA isolation, amplification and labeling as described elsewhere [1, 4, 11]. Tumors were classified as a 70-gene signature low or high risk at the time of the initial studies. Low risk was defined as an index score greater than 0.4. High risk was defined as an index score lower than 0.4 [1, 11].

Statistical analysis

For this analysis, we estimated overall survival (OS) and distant metastasis-free survival (DMFS). DMFS was defined as time from diagnosis to distant metastasis as first event. Data on all other patients were censored on the last date of follow-up, in the event of a second primary tumor including contralateral breast cancer, in case of death from any cause other than breast cancer, or if there was a local–regional recurrence of the disease. In case a local–regional recurrence was followed by distant metastasis within 6 months, the event of distant metastasis was included in the analysis. Survival curves were constructed using the Kaplan–Meier method and compared using the log-rank test. Competing risk analyses were performed to adjust for patients having a type of event (for example death due to another cause than breast cancer) that makes them unable to develop the event of interest. The hazard ratios (HRs) of the 70-gene signature were calculated for the full follow-up as well as per 5-year intervals. A significant finding was defined as a p value below 0.05. Analyses were performed using SAS version 9.2 and R version 2.14.0.

Results

NKI 295: patient and tumor characteristics

Patient characteristics are described in Supplementary Table 1 [4]. Of the 295 patients, 115 patients had a low-risk 70-gene signature and 180 had a high-risk 70-gene signature. Patients with a low-risk 70-gene signature were more often of older age and had more often smaller estrogen-receptor (ER)-positive tumors with lower grade. No significant difference between patients with low- and high-risk 70-gene signature was seen for number of positive nodes, vascular invasion and treatment (type of surgery, adjuvant chemotherapy nor adjuvant endocrine therapy). Thirty-seven percent of the patients received adjuvant chemotherapy, and 14 % received adjuvant endocrine therapy. After a median follow-up of 18.5 years, 121 patients developed distant metastasis as first event. One hundred and twenty-seven patients have died, of whom 114 died due to breast cancer.

Long-term prognostic value of the 70-gene signature

Figure 1 shows DMFS and OS for the entire cohort (1A), and separately for node-negative (1B) and node-positive patients (1C). The Kaplan–Meier curves showed a significant absolute difference in DMFS and OS at 25 years between the patients with a low-risk 70-gene signature (60.4 and 57.3 % respectively) and the patients with a high-risk 70-gene signature (41.6 and 44.5 % respectively; p < 0.0001 for both OS and DMFS). This significant difference was observed for node-negative (p < 0.0001 for both OS and DMFS) as well as node-positive patients (p = 0.03 for OS and p = 0.0004 for DMFS). Conditional survival probabilities for all patients and both subgroups for 5, 10, 15, 20 and 25 years are summarized in Table 1. The 25-year HRs for all patients for DMFS and OS were 3.1 (95 % CI 2.02–4.86) and 2.9 (95 % CI 1.90–4.28), respectively. The HR for DMFS in the first 5 years after diagnosis was 9.6 (95 % CI 4.2–22.1) and 11.3 (95 % CI 3.5–36.4) for OS. After 5 years, the effect of the 70-gene signature on DMFS diminished, while the effect on OS from years 5 to 10 after diagnosis was still very significant with a HR 6.1 (95 % CI 2.4–15.6). After 15 years, the effect of the 70-gene signature on OS slowly diminished (Table 2). The 25-year HRs for node-negative patients for DMFS and OS were 4.57 (95 % CI 2.31–9.04) and 4.73 (95 % CI 2.46–9.07), respectively. The 25-year HRs for node-positive patients for DMFS and OS were 2.24 (95 % CI 1.25–4.00) and 1.83 (95 % CI 1.07–3.11), respectively.

Fig. 1

Overall survival (OS) and distant metastasis-free survival (DMFS) for all patients and stratified by nodal status

Table 1

Distant metastasis-free survival (DMFS) and overall survival (OS) probabilities for all patients and stratified by nodal status

Group	No. of patients	5 years	10 years	15 years	20 years	25 years
DMFS (95 % CI)
All patients	295
Low risk	115	94.7 (90.7–98.9)	82.0 (75–89.7)	78.1 (70.3–86.8)	75.9 (67.3–85.5)	60.4 (45.3–80.5)
High risk	180	58.5 (51.6–66.4)	50.0 (42.8–58.4)	47.1 (39.7–55.8)	44.8 (36.9–54.5)	41.6 (32.6–53.1)
Node-negative	151
Low risk	60	94.9 (89.5–100)	85.6 (76.8–95.4)	85.6 (76.8–95.4)	81.3 (70.1–94.3)	73.2 (56.7–94.3)
High risk	91	52.4 (42.8–64.2)	45.6 (36.0–57.8)	44.0 (34.4–56.3)	39.6 (28.7–54.6)	39.6 (28.7–54.6)
Node-positive	144
Low risk	55	94.5 (88.7–100)	78.6 (68.1–90.7)	70.3 (58.1–85.1)	70.3 (58.1–85.1)	No pt at risk
High risk	89	64.7 (55.3–75.8)	54.3 (44.2–66.6)	50.1 (39.7–63.3)	50.1 (39.7–63.3)	44.5 (32.1–61.8)
OS (95 %CI)
All patients	295
Low risk	115	97.4 (94.5–100)	92.8 (88.2–97.8)	83.0 (75.9–90.8)	69.4 (60–80.2)	57.3 (44.8–73.2)
High risk	180	74.0 (67.8–80.7)	55.7 (48.7–63.6)	47.7 (70.7–56)	42.0 (34.6–51.1)	39.7 (31.7–49.8)
Node-negative	151
Low risk	60	96.7 (92.2–100)	93.2 (87–99.9)	89.1 (81.2–97.8)	82.1 (72.0–93.6)	69.5 (52.3–92.2)
High risk	91	71.1 (62.4–81.1)	52.7 (43.2–64.2)	44.3 (34.9–56.1)	37.8 (28.0–50.9)	33.6 (23.0–49)
Node-positive	144
Low risk	55	98.2 (94.7–100)	92.5 (85.7–99.9)	76.6 (65.2–89.9)	54.5 (40–74.2)	42.2 (26.6–67.5)
High risk	89	76.9 (68.5–86.3)	58.7 (49.1–70.3)	51.1 (41.6–63.8)	47.1 (36.8–60.3)	47.1 (36.8–60.3)

Table 2

Hazard ratios for the 70-gene signature for OS and DMFS

	At risk	Events	HR	95 % CI
DMFS (years)
0–25	295	111	3.1	2.02–4.86
0–5	295	74	9.6	4.2–22.1
5–10	196	23	1.1	0.5–2.5
10–15	145	6	1.2	0.2–6.0
15–20	94	2	1.1	0.1–17.9
20–25	40	6	0.3	0–2.9
OS (years)
0–25	295	127	2.9	1.9–4.28
0–5	295	49	11.3	3.5–36.4
5–10	240	36	6.1	2.4–15.6
10–15	191	21	1.5	0.6–3.5
15–20	131	15	0.6	0.2–1.7
20–25	64	6	0.2	0–2.1

Distant metastases and competing events

Figure 2 demonstrates how competing events that occurred in this cohort in addition to distant metastases are divided over the 70-gene signature low- and high-risk groups. The 70-gene signature low versus high risk in this cohort was only significant for prediction of distant metastases, as shown in Fig. 1; Table 1.

Fig. 2

Competing risk analysis

For the DMFS analyses, locoregional recurrence was considered a competing event, and therefore, follow-up was censored if occurred first, except when the locoregional event took place within 6 months prior to the distant metastasis. Reanalysing the data without including the locoregional events that occur within 6 months before the patient is diagnosed with distant metastases, gives no substantial difference in survival probabilities (data not shown).

Discussion

This update of the consecutive 295 patient cohort shows that the 70-gene signature is able to accurately differentiate between patients at a low and a high risk of distant metastases up to 25 years after diagnosis. This gene signature was designed to predict the risk of distant metastases in the first 5 years after diagnosis. Previous analyses by Buyse et al. already confirmed that the 70-gene signature has prognostic value in the first 5 years after diagnosis [3]. Their analyses also suggested that this effect might be present up to 10 years after diagnosis. In our analyses, the 70-gene signature has the largest prognostic value for DMFS and OS in the first 5 years (HRs 9.6 (95 % CI 4.2–22.1) and 11.3 (95 % CI 3.5–36.4) respectively). The significant prognostic value per 5-year intervals for OS remained from 5 years after diagnosis onwards and becomes smaller after 15 years.

Meta-analyses of patients with breast cancer have shown that adjuvant chemotherapy reduces the rate of recurrence almost exclusively in the first 5 years [12]. Consequently, one would expect that patients with relapse in the first 5 years after surgery will benefit most from adjuvant chemotherapy. Thus, for the question of who should receive adjuvant chemotherapy, it is most relevant to identify the patients with relapse in the first 5 years after surgery. That the 70-gene signature has the highest HR for recurrence in the first 5 years supports the notion that this test can help identify those patients that are most likely to benefit from adjuvant chemotherapy. The Food and Drug Administration (FDA) 510-(k) cleared intended use of the 70-gene signature for prognosis prediction in the node-negative, systemically untreated patient population (IVDMIA k101454). The node-negative subgroup of this consecutive series, of whom over 85 % did not receive adjuvant systemic therapy, most closely represents this population; it is shown here that for node-negative patients, long-term outcome can also be predicted using the 70-gene prognosis signature.

Patients included in this cohort were all diagnosed between 1984 and 1995. Due to improvement in adjuvant systemic treatment and the introduction of nation-wide screening programs, which resulted in an increase in early-stage breast cancer and a decrease in breast cancer mortality rates, one could hypothesize that the survival probabilities of this cohort if diagnosed today would be even better than shown here [10]. Also of note, the patients included were all younger than 53 years old, who tend to have a poorer prognosis compared to patients diagnosed at older age [13, 14].

In conclusion, an update of the 70-gene signature consecutive 295 patient cohort shows that the 70-gene signature has long-term prognostic value in patients <53 years old with stage I and II breast cancer.

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 18 kb)